Avalo Therapeutics Inc.

NASDAQ: AVTX · Real-Time Price · USD
9.05
0.10 (1.12%)
At close: Aug 15, 2025, 3:59 PM
9.24
2.10%
After-hours: Aug 15, 2025, 07:50 PM EDT

Avalo Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-35.13M -31.54M -41.66M -84.38M
Depreciation & Amortization
169K 158K 166K 1.66M
Stock-Based Compensation
5.85M 3.48M 7.55M 8.17M
Other Working Capital
-4.54M -8.61M 4.18M 961K
Other Non-Cash Items
-15.35M 6.46M 2.39M 794K
Deferred Income Tax
114K 14K 28K 22K
Change in Working Capital
-4.71M -9.24M 4.77M 2.84M
Operating Cash Flow
-49.06M -30.68M -26.75M -70.89M
Capital Expenditures
n/a -158K -95K -113K
Cash Acquisitions
n/a n/a n/a n/a
Purchase of Investments
n/a n/a n/a n/a
Sales Maturities Of Investments
n/a n/a n/a n/a
Other Investing Acitivies
356K 25K n/a n/a
Investing Cash Flow
356K -133K -95K -113K
Debt Repayment
n/a -21.24M n/a 32.9M
Common Stock Repurchased
68K n/a -14.81M n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
60.22M 67K -14.7M 1.93M
Financial Cash Flow
175.85M 25.04M -14.7M 106.76M
Net Cash Flow
127.15M -5.77M -41.55M 35.76M
Free Cash Flow
-49.06M -30.84M -26.85M -71M